Thomas R. Cannell
2016 - Orexigen Therapeutics
In 2016, Thomas R. Cannell earned a total compensation of $2.7M as Executive Vice President, Chief Operating Officer and President of Global Commercial Products at Orexigen Therapeutics, a 18% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $237,559 |
|---|---|
| Option Awards | $1,655,000 |
| Salary | $445,081 |
| Stock Awards | $378,000 |
| Other | $8,466 |
| Total | $2,724,106 |
Cannell received $1.7M in option awards, accounting for 61% of the total pay in 2016.
Cannell also received $237.6K in non-equity incentive plan, $445.1K in salary, $378K in stock awards and $8.5K in other compensation.
Rankings
In 2016, Thomas R. Cannell's compensation ranked 3,574th out of 14,075 executives tracked by ExecPay. In other words, Cannell earned more than 74.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,574 out of 14,075 | 75th |
Division Manufacturing | 1,244 out of 5,489 | 77th |
Major group Chemicals And Allied Products | 378 out of 1,895 | 80th |
Industry group Drugs | 275 out of 1,538 | 82nd |
Industry Pharmaceutical Preparations | 218 out of 1,176 | 82nd |
Source: SEC filing on May 30, 2017.
Cannell's colleagues
We found two more compensation records of executives who worked with Thomas R. Cannell at Orexigen Therapeutics in 2016.
News
Eleven Biotherapeutics CEO Steven Kelly receives $3.5M in 2023
April 29, 2024
Eleven Biotherapeutics CEO Thomas Cannell's 2022 pay falls 72% to $1.4M
April 28, 2023
Eleven Biotherapeutics CEO Thomas Cannell's 2021 pay jumps 189% to $4.9M
April 28, 2022
Eleven Biotherapeutics CEO Thomas Cannell's 2020 pay jumps 21% to $1.7M
March 25, 2021
Eleven Biotherapeutics CEO Thomas Cannell's 2019 pay falls 30% to $1.4M
March 30, 2020
Eleven Biotherapeutics CEO Thomas Cannell receives $2M in 2018
April 30, 2019